SEP 10, 2020 10:00 AM PDT

PGT-A simplified. Which of the leading NGS solutions is easiest to implement?

  • Director of Preimplantation Genetics, NxGen MDx
      Adam Goodman is a graduate of the University of Michigan and trained for many years, at the Reproductive Genetics Institute in Chicago, under Yuri Verlinsky, one of the founding fathers of preimplantation genetics. There he helped the lab become one of the first to utilize NGS technology for the detection of aneuploidy in human embryos. He is currently the Director of Preimplantation Genetics at NxGen MDx and has been working in this field for over a decade, playing an essential role in the adoption of evolving PGT technologies for multiple reference labs.


    DATE: September 10, 2020

    TIME: 10:00am PST, 1:00pm EST


    The vast majority of preimplantation genetic testing for aneuploidy (PGT-A) in the United States is performed using one of two NGS-based platforms, the VeriSeq-PGS platform from Illumina or the Ion ReproSeq-PGS platform from Thermo Fisher Scientific. However, there are few head-to-head data available comparing the two assays. Join us for this webinar, where Adam Goodman will demonstrate how their team assessed the performance of these two platforms when selecting the assay that best suited the needs of their lab. Adam will also discuss how sample noise can lead to the mislabeling of a sample as mosaic. 


    Learning Objectives:

    • Learn how to investigate important PGT-A assay metrics, such as accuracy, precision, throughput, ease of use, and total cost
    • Gain working knowledge of how to test the limits of detection of a PGT-A assay, both with regards to resolution and mosaicism 
    • Discover how the two leading PGT-A platforms leverage sequencing data to interpret copy number variation



    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

    Show Resources
    Show Resources
    • See more
    Connect with us